Beyond Antibiotics

超越抗生素

• 批准号: EP/V026623/1
• 负责人: Eleanor Stride
• 金额: $ 834.94万
• 依托单位: University of Oxford
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FV026623%2F1
• 关键词: Beyond; Antibiotics

The 2019 World Health Organisation (WHO) report on Antimicrobial Resistance (AMR) identifies it as: "one of the greatest threats we face as a global community." The evolution of drug-resistant bacteria, our over-use of antibiotics and failure to develop new methods for tackling infection could leave us without viable treatments for even the most trivial infections within the next 3 decades. There have been significant efforts by the WHO and national agencies to raise awareness of AMR and reduce the use of antibiotics, but there is still an urgent need to intensify these efforts and, crucially, to develop alternatives. The aim of the programme is to address this need.The programme will consist of 4 interlinked work packages focussed on the core research objectives: (1) The development of human organoid models for studying interactions between bacteria and the tissue microenvironment and larger scale interactions with the host microbiome. (2) New microscopy methods to complement the organoid models and to facilitate rapid characterisation of bacteria for improved diagnosis.(3) New antimicrobial therapeutics and targeted delivery techniques to improve the use of existing antibiotics and provide viable alternatives.(4) "Drug-free" methods for treating infections and promoting immune function thereby further reducing the use of antibiotics and providing methods suitable for large scale environmental/industrial use.These will be supported by 2 parallel translational activities to enable development of the translational pathway and wider engagement with clinical and industrial stakeholders, policy-makers and the public.

在2019年世界卫生组织(WHO)关于抗菌素耐药性(AMR)的报告中，它被确定为：“作为一个全球社会，我们面临的最大威胁之一。”抗药性细菌的进化，我们过度使用抗生素，以及未能开发出应对感染的新方法，可能会让我们在未来30年内找不到可行的治疗方法，即使是最轻微的感染。世卫组织和国家机构在提高对AMR的认识和减少抗生素的使用方面做出了重大努力，但仍迫切需要加强这些努力，尤其是开发替代品。该方案的目的是满足这一需求。该方案将由4个相互关联的工作包组成，集中于核心研究目标：(1)开发用于研究细菌与组织微环境之间的相互作用以及与宿主微生物组的更大规模相互作用的人体有机模型。(2)新的显微镜方法，以补充有机物模型，并促进细菌的快速鉴定，以改进诊断。(3)新的抗微生物疗法和定向递送技术，以改进现有抗生素的使用，并提供可行的替代方法。(4)治疗感染和促进免疫功能的“无药物”方法，从而进一步减少抗生素的使用，并提供适合大规模环境/工业使用的方法。这些方法将由2个平行的翻译活动支持，以开发翻译途径，并与临床和工业利益攸关方、政策制定者和公众进行更广泛的接触。

项目成果

A human urothelial microtissue model reveals shared colonization and survival strategies between uropathogens and commensals.

• DOI: 10.1126/sciadv.adi9834
• 发表时间: 2023-11-10
• 期刊: Science advances
• 影响因子: 13.6
• 作者: Flores C;Ling J;Loh A;Maset RG;Aw A;White IJ;Fernando R;Rohn JL
• 通讯作者: Rohn JL

Compressed sensing for electron cryotomography and high-resolution subtomogram averaging of biological specimens.

• DOI: 10.1016/j.str.2021.12.010
• 发表时间: 2022-03-03
• 期刊: Structure (London, England : 1993)
• 作者: Böhning J;Bharat TAM;Collins SM
• 通讯作者: Collins SM

Facile production of quercetin nanoparticles using 3D printed centrifugal flow reactors.

• DOI: 10.1039/d2ra02745c
• 发表时间: 2022-07-14
• 期刊: RSC advances
• 影响因子: 3.9

Early biofilm and streamer formation is mediated by wall shear stress and surface wettability: A multifactorial microfluidic study.

• DOI: 10.1002/mbo3.1310
• 发表时间: 2022-08
• 期刊: MICROBIOLOGYOPEN
• 影响因子: 3.4
• 作者: Chun, Alexander L. M.;Mosayyebi, Ali;Butt, Arthur;Carugo, Dario;Salta, Maria
• 通讯作者: Salta, Maria

Cryo-EM samples of gas-phase purified protein assemblies using native electrospray ion-beam deposition.

• DOI: 10.1039/d2fd00065b
• 发表时间: 2022-11-08
• 期刊: FARADAY DISCUSSIONS
• 影响因子: 3.4
• 作者: Esser, Tim K.;Bohning, Jan;Fremdling, Paul;Bharat, Tanmay;Gault, Joseph;Rauschenbach, Stephan
• 通讯作者: Rauschenbach, Stephan